Aufsatzsammlung
Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Maße
-
28 cm
- Umfang
-
11, 2 Seiten
- Sprache
-
Deutsch
- Anmerkungen
-
Illustrationen, Diagramme
- Klassifikation
-
Medizin, Gesundheit
- Ereignis
-
Veröffentlichung
- (wo)
-
Stuttgart
- (wer)
-
Thieme
- (wann)
-
April 2023
- Beteiligte Personen und Organisationen
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 14:18 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Aufsatzsammlung
Beteiligte
- Hartkopf, Andreas
- Thieme
Entstanden
- April 2023
Ähnliche Objekte (12)
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Circulating and Disseminated Tumor Cells in Breast Carcinoma : Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
Update breast cancer 2023 Part 1 – early stage breast cancer
Trastuzumab-Deruxtecan (Enhertu) : Antikörper-Wirkstoff-Konjugat der neuen Generation zur Behandlung von nicht-operablem oder metastasiertem HER2-positivem Brustkrebs
Circulating and Disseminated Tumour Cells in Breast Carcinoma : Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry
The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Circulating and Disseminated Tumor Cells in Breast Carcinoma : Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
Update breast cancer 2023 Part 1 – early stage breast cancer
Trastuzumab-Deruxtecan (Enhertu) : Antikörper-Wirkstoff-Konjugat der neuen Generation zur Behandlung von nicht-operablem oder metastasiertem HER2-positivem Brustkrebs
Circulating and Disseminated Tumour Cells in Breast Carcinoma : Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry
The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Circulating and Disseminated Tumor Cells in Breast Carcinoma : Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
Update breast cancer 2023 Part 1 – early stage breast cancer
Trastuzumab-Deruxtecan (Enhertu) : Antikörper-Wirkstoff-Konjugat der neuen Generation zur Behandlung von nicht-operablem oder metastasiertem HER2-positivem Brustkrebs
Circulating and Disseminated Tumour Cells in Breast Carcinoma : Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry
The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine